Literature DB >> 29509436

Developmental origins of nonalcoholic fatty liver disease as a risk factor for exaggerated metabolic and cardiovascular-renal disease.

Frank T Spradley1,2,3, Jillian A Smith1, Barbara T Alexander2,3, Christopher D Anderson1,2.   

Abstract

Intrauterine growth restriction (IUGR) is linked to increased risk for chronic disease. Placental ischemia and insufficiency in the mother are implicated in predisposing IUGR offspring to metabolic dysfunction, including hypertension, insulin resistance, abnormalities in glucose homeostasis, and nonalcoholic fatty liver disease (NAFLD). It is unclear whether these metabolic disturbances contribute to the developmental origins of exaggerated cardiovascular-renal disease (CVRD) risk accompanying IUGR. IUGR impacts the pancreas, adipose tissue, and liver, which are hypothesized to program for hepatic insulin resistance and subsequent NAFLD. NAFLD is projected to become the major cause of chronic liver disease and contributor to uncontrolled type 2 diabetes mellitus, which is a leading cause of chronic kidney disease. While NAFLD is increased in experimental models of IUGR, lacking is a full comprehension of the mechanisms responsible for programming of NAFLD and whether this potentiates susceptibility to liver injury. The use of well-established and clinically relevant rodent models, which mimic the clinical characteristics of IUGR, metabolic disturbances, and increased blood pressure in the offspring, will permit investigation into mechanisms linking adverse influences during early life and later chronic health. The purpose of this review is to propose mechanisms, including those proinflammatory in nature, whereby IUGR exacerbates the pathogenesis of NAFLD and how these adverse programmed outcomes contribute to exaggerated CVRD risk. Understanding the etiology of the developmental origins of chronic disease will allow investigators to uncover treatment strategies to intervene in the mother and her offspring to halt the increasing prevalence of metabolic dysfunction and CVRD.

Entities:  

Keywords:  hypertension; inflammation; insulin resistance; placental ischemia; steatosis

Mesh:

Year:  2018        PMID: 29509436      PMCID: PMC6293166          DOI: 10.1152/ajpendo.00394.2017

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  238 in total

Review 1.  The impact of IUGR on pancreatic islet development and β-cell function.

Authors:  Brit H Boehmer; Sean W Limesand; Paul J Rozance
Journal:  J Endocrinol       Date:  2017-08-14       Impact factor: 4.286

2.  Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up.

Authors:  Mattias Ekstedt; Hannes Hagström; Patrik Nasr; Mats Fredrikson; Per Stål; Stergios Kechagias; Rolf Hultcrantz
Journal:  Hepatology       Date:  2015-03-23       Impact factor: 17.425

3.  Metformin treatment to reduce central adiposity after prenatal growth restraint: a placebo-controlled pilot study in prepubertal children.

Authors:  Marta Díaz; Judit Bassols; Abel López-Bermejo; Francis de Zegher; Lourdes Ibáñez
Journal:  Pediatr Diabetes       Date:  2014-10-20       Impact factor: 4.866

Review 4.  Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action.

Authors:  Fernando Bril; Kenneth Cusi
Journal:  Diabetes Care       Date:  2017-03       Impact factor: 19.112

5.  Leptin and adiponectin concentrations in intrauterine growth restricted and appropriate for gestational age fetuses, neonates, and their mothers.

Authors:  Marialena Kyriakakou; Ariadne Malamitsi-Puchner; Helen Militsi; Theodora Boutsikou; Alexandra Margeli; Demetrios Hassiakos; Christina Kanaka-Gantenbein; Ioannis Papassotiriou; George Mastorakos
Journal:  Eur J Endocrinol       Date:  2008-03       Impact factor: 6.664

6.  Overexpression of sterol regulatory element-binding protein-1a in mouse adipose tissue produces adipocyte hypertrophy, increased fatty acid secretion, and fatty liver.

Authors:  Jay D Horton; Iichiro Shimomura; Shinji Ikemoto; Yuriy Bashmakov; Robert E Hammer
Journal:  J Biol Chem       Date:  2003-07-10       Impact factor: 5.157

7.  Maternal obesity at conception programs obesity in the offspring.

Authors:  Kartik Shankar; Amanda Harrell; Xiaoli Liu; Janet M Gilchrist; Martin J J Ronis; Thomas M Badger
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2007-11-21       Impact factor: 3.619

8.  Increased susceptibility of prenatal food restricted offspring to high-fat diet-induced nonalcoholic fatty liver disease is intrauterine programmed.

Authors:  Li Zhang; Lang Shen; Dan Xu; Linlong Wang; Yuming Guo; Zhongfen Liu; Yansong Liu; Lian Liu; Jacques Magdalou; Liaobin Chen; Hui Wang
Journal:  Reprod Toxicol       Date:  2016-08-16       Impact factor: 3.143

9.  Obesity, Visceral Fat, and NAFLD: Querying the Role of Adipokines in the Progression of Nonalcoholic Fatty Liver Disease.

Authors:  M S Mirza
Journal:  ISRN Gastroenterol       Date:  2011-08-28

Review 10.  Impaired adipose tissue expandability and lipogenic capacities as ones of the main causes of metabolic disorders.

Authors:  Isabel Moreno-Indias; Francisco José Tinahones
Journal:  J Diabetes Res       Date:  2015-04-02       Impact factor: 4.011

View more
  3 in total

1.  Alterations in DNA methylation associate with fatty liver and metabolic abnormalities in a multi-ethnic cohort of pre-teenage children.

Authors:  Cynthia A Moylan; Alisha M Mavis; Dereje Jima; Rachel Maguire; Mustafa Bashir; Jeongeun Hyun; Melanie N Cabezas; Alice Parish; Donna Niedzwiecki; Anna Mae Diehl; Susan K Murphy; Manal F Abdelmalek; Cathrine Hoyo
Journal:  Epigenetics       Date:  2022-02-21       Impact factor: 4.861

2.  Liver Proteome Profile of Growth Restricted and Appropriately Grown Newborn Wistar Rats Associated With Maternal Undernutrition.

Authors:  Polyxeni-Maria Sarli; Antigoni Manousopoulou; Elias Efthymiou; Andreas Zouridis; Anastasios Potiris; Panagiota Pervanidou; Konstantinos Panoulis; Nikolaos Vlahos; Efthymios Deligeoroglou; Spiros D Garbis; Makarios Eleftheriades
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-28       Impact factor: 5.555

3.  Adrenergic receptor blockade attenuates placental ischemia-induced hypertension.

Authors:  Frank T Spradley; Ying Ge; B Peyton Haynes; Joey P Granger; Christopher D Anderson
Journal:  Physiol Rep       Date:  2018-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.